NCT01270906View on ClinicalTrials.gov

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

October 31, 2006

Conditions

NeoplasmsCancerTumors

Interventions

DRUG

CHIR-258 (TKI258)

Trial Locations (2)

Unknown

Novartis Investigative Site, Glasgow

Novartis Investigative Site, Sutton

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Collaborators (1)

Chiron Corporation

All Listed Sponsors

collaborator

Chiron Corporation

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY